S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
The 32-Second Options Trading "Training Video" Retirees Can't Get Enough Of (Ad)
NASDAQ:ARAY

Accuray - ARAY Stock Forecast, Price & News

$2.92
+0.10 (+3.55%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.74
$2.92
50-Day Range
$1.76
$2.97
52-Week Range
$1.70
$5.93
Volume
542,830 shs
Average Volume
926,335 shs
Market Capitalization
$270.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.33

Accuray MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
151.1% Upside
$7.33 Price Target
Short Interest
Bearish
5.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.61mentions of Accuray in the last 14 days
Based on 25 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
1,800.00%
From $0.01 to $0.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

276th out of 1,122 stocks

Surgical & Medical Instruments Industry

28th out of 112 stocks

ARAY stock logo

About Accuray (NASDAQ:ARAY) Stock

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. TheStreet lowered Accuray from a "c-" rating to a "d" rating in a report on Thursday, April 28th. B. Riley initiated coverage on shares of Accuray in a research note on Thursday, June 23rd. They issued a "buy" rating and a $7.50 price target for the company. BTIG Research lowered their price objective on shares of Accuray from $9.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday, June 24th. Finally, StockNews.com cut Accuray from a "buy" rating to a "hold" rating in a report on Tuesday. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $7.33.

Accuray Price Performance

Accuray stock traded up $0.10 during mid-day trading on Wednesday, hitting $2.92. The company's stock had a trading volume of 542,830 shares, compared to its average volume of 926,335. The stock has a market capitalization of $270.98 million, a P/E ratio of -47.17 and a beta of 1.82. Accuray has a twelve month low of $1.70 and a twelve month high of $5.93. The stock's fifty day moving average price is $2.11 and its two-hundred day moving average price is $2.74. The company has a quick ratio of 1.04, a current ratio of 1.72 and a debt-to-equity ratio of 3.36.

Accuray (NASDAQ:ARAY - Get Rating) last announced its earnings results on Wednesday, August 10th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. Accuray had a negative return on equity of 10.81% and a negative net margin of 1.24%. During the same quarter last year, the firm earned ($0.01) EPS. Research analysts forecast that Accuray will post 0.01 earnings per share for the current year.

Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Stock News Headlines

Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
Accuray Incorporated Q4 Loss Narrows
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Accuray (NASDAQ:ARAY) Raised to Buy at StockNews.com
See More Headlines
Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

ARAY Company Calendar

Last Earnings
8/10/2022
Today
8/17/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ARAY
CUSIP
00439710
Employees
995
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$7.33
High Stock Price Forecast
$7.50
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+151.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-5,350,000.00
Pretax Margin
-2.62%

Debt

Sales & Book Value

Annual Sales
$429.91 million
Cash Flow
$0.12 per share
Book Value
$0.74 per share

Miscellaneous

Free Float
89,090,000
Market Cap
$270.98 million
Optionable
Optionable
Beta
1.82

Social Links















ARAY Stock - Frequently Asked Questions

Should I buy or sell Accuray stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARAY shares.
View ARAY analyst ratings
or view top-rated stocks.

What is Accuray's stock price forecast for 2022?

3 Wall Street research analysts have issued 1-year target prices for Accuray's stock. Their ARAY share price forecasts range from $7.00 to $7.50. On average, they expect the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 151.1% from the stock's current price.
View analysts price targets for ARAY
or view top-rated stocks among Wall Street analysts.

How have ARAY shares performed in 2022?

Accuray's stock was trading at $4.77 at the start of the year. Since then, ARAY stock has decreased by 38.8% and is now trading at $2.92.
View the best growth stocks for 2022 here
.

When is Accuray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ARAY earnings forecast
.

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) released its earnings results on Wednesday, August, 10th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02. Accuray had a negative trailing twelve-month return on equity of 10.81% and a negative net margin of 1.24%. During the same period in the previous year, the company earned ($0.01) earnings per share.

What guidance has Accuray issued on next quarter's earnings?

Accuray updated its FY 2023 earnings guidance on Friday, August, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $447.00 million-$455.00 million, compared to the consensus revenue estimate of $425.20 million.

What is Joshua Levine's approval rating as Accuray's CEO?

107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Who are Accuray's major shareholders?

Accuray's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (3.96%), Royce & Associates LP (2.85%), Assenagon Asset Management S.A. (1.78%), Millennium Management LLC (1.20%), State Street Corp (0.86%) and Lapides Asset Management LLC (0.85%). Insiders that own company stock include Andrew J Kirkpatrick, Brandon W Green, Byron C Scott, Jesse Chew, Joseph E Whitters, Joshua Levine, Michael Hoge, Patrick Spine, Shigeyuki Hamamatsu and Suzanne C Winter.
View institutional ownership trends
.

How do I buy shares of Accuray?

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accuray's stock price today?

One share of ARAY stock can currently be purchased for approximately $2.92.

How much money does Accuray make?

Accuray (NASDAQ:ARAY) has a market capitalization of $270.98 million and generates $429.91 million in revenue each year. The medical equipment provider earns $-5,350,000.00 in net income (profit) each year or ($0.06) on an earnings per share basis.

How many employees does Accuray have?

The company employs 995 workers across the globe.

Does Accuray have any subsidiaries?
The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.
Read More
When was Accuray founded?

Accuray was founded in 1990.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The official website for the company is www.accuray.com. The medical equipment provider can be reached via phone at (408) 716-4600, via email at mpolyviou@evcgroup.com, or via fax at 408-716-4601.

This page (NASDAQ:ARAY) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.